8/13/2020  8:00:54 AM Chg. -0.35 Volume Bid6:59:00 PM Ask6:59:00 PM Market Capitalization Dividend Y. P/E Ratio
246.65EUR -0.14% 0
Turnover: 0.00
245.80Bid Size: 205 246.05Ask Size: 205 39.18 bill.EUR - -

Business description

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
 

Management board & Supervisory board

CEO
Michel Vounatsos
Management board
Jeffrey D. Capello (ab 15.08.2020), Michael (Mike) McDonnell (ab 15.08.2020), Alfred Sandrock, Alphonse Galdes, Chirfi Guindo, Dr. Ginger Gregory, Susan H. Alexander
Supervisory board
Dr. Stelios Papadopoulos, Brian S. Posner, Caroline Dorsa, Dr. Alexander J. Denner, Dr. Richard C. Mulligan, Eric K. Rowinsky, Jesus B. Mantas, Michel Vounatsos, Nancy L. Leaming, Robert W. Pangia, Stephen A. Sherwin, William A. Hawkins
 

Company data

Name: Biogen Inc.
Address: 225 Binney Street,Cambridge, Massachusetts 02142, USA
Phone: +1-671-679-2000
Fax: +1-617-679-2617
E-mail: -
Internet: www.biogen.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 75.20%
IPO date: -

Investor relations

Name: Joe Mara
IR phone: +1-781-464-2442
IR Fax: -
IR e-mail: IR@biogenidec.com

Main Shareholders

Freefloat
 
75.20%
BlackRock, Inc.
 
8.70%
PRIMECAP Management Company
 
8.42%
The Vanguard Group
 
7.68%